ASXL1 and Splenomegaly: DIPSS-plus10risk distribution was 63% high, 36% intermediate-2, and 1% intermediate-1; 49% of the patients displayed red cell transfusion need, 58% constitutional symptoms, 87% palpable splenomegaly >5 cm, and 50% abnormal karyotype; 94 patients were screened for ASXL1 mutations with 41 (44%) mutated and 78 for SRSF2 mutations with 14 (18%) mutated; 21 (21%) patients were previously treated with another JAK inhibitor.